Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AI-TCRm17-6
- Development stage
- Unknown
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
**AI-TCRm17-6** is an investigational **T cell receptor (TCR) mimic monoclonal antibody** developed using artificial intelligence-driven approaches for targeted cancer therapy. It binds to peptide-major histocompatibility complex (pMHC) neoantigens presented on tumor cells, enabling precise recognition and T cell-mediated cytotoxicity against cancer cells expressing specific mutated peptides. Likely developed by an AI-focused biotech company, it represents an advanced immunotherapy modality designed to overcome limitations of natural TCRs with higher affinity and specificity, potentially for solid tumors harboring actionable neoantigens.
Beyond the preview
Go deeper on AI-TCRm17-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AI-TCRm17-6.